GRI Bio, Inc. (GRI)
| Market Cap | 1.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.77M |
| Shares Out | 1.02M |
| EPS (ttm) | 208.91 |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 457,280 |
| Open | 1.260 |
| Previous Close | 1.270 |
| Day's Range | 1.170 - 1.310 |
| 52-Week Range | 1.150 - 343.070 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2024 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells t... [Read more]
Financial Performance
Financial StatementsNews
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
Live video webcast on Wednesday, July 17 th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology compa...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio Regains Compliance with Nasdaq
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modula...
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice
GRI Bio to Present at the 8th Annual IPF Summit
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Closing of $4.0 Million Public Offering
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Comp...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14 th International Congress on Autoimmunity
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Data presented at the 14 th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projecte...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score ...
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21 st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancin...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modul...
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innova...
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modul...
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an inn...
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topl...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
GRI Bio Announces Pricing of $5.5 Million Public Offering
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, lim...